Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;34(4):1057-1067.
doi: 10.1007/s40620-020-00930-x. Epub 2021 Feb 8.

Systolic blood pressure and chronic kidney disease progression in patients with primary glomerular disease

Hyung Woo Kim  1 , Jung Tak Park  1 , Young Su Joo  1   2 , Shin Chan Kang  1 , Jee Young Lee  1 , Sangmi Lee  1 , Tae Ik Chang  3 , Ea Wha Kang  3 , Dong-Ryeol Ryu  4 , Tae-Hyun Yoo  1 , Ho Jun Chin  5 , Shin-Wook Kang  1 , Seung Hyeok Han  6 ; Korean GlomeruloNEphritis Study (KoGNET) Group
Affiliations

Systolic blood pressure and chronic kidney disease progression in patients with primary glomerular disease

Hyung Woo Kim et al. J Nephrol. 2021 Aug.

Abstract

Introduction: Many current guidelines on optimal target blood pressure (BP) for chronic kidney disease (CKD) patients are largely based on studies in diabetic and hypertensive patients. However, there have been few studies in patients with glomerular diseases.

Methods: We retrospectively studied the longitudinal association between BP and CKD progression in 1,066 biopsy-proven patients diagnosed with primary glomerular diseases, including IgA nephropathy, membranous nephropathy (MN), and focal segmental glomerulosclerosis (FSGS), between 2005 and 2017. The main predictor was time-updated systolic blood pressure (SBP) at every clinic visit. The primary outcome was a composite one including ≥ 50% decrease in estimated glomerular filtration rate (eGFR) from the baseline, and end-stage kidney disease (ESKD).

Results: During 5009 person-years of follow-up, the primary outcome occurred in 157 (14.7%) patients. In time-varying Cox model, the adjusted hazard ratios (HRs) (95% confidence interval (CI)) for the primary outcome were 1.48 (0.96-2.29), 2.07 (1.22-3.52), and 2.53 (1.13-5.65) for SBP of 120-129, 130-139, and ≥ 140 mmHg, respectively, compared with SBP < 120 mmHg. This association was particularly evident in patients with elevated proteinuria. However, there was no association between baseline SBP and adverse kidney outcomes. Finally, prediction models failed to show the improvement of predictive performance of SBP compared with that of remission status. Moreover, patients with remission and less controlled SBP had better kidney outcomes than those with non-remission and well-controlled SBP.

Conclusion: Among patients with glomerular disease, higher time-updated SBP was significantly associated with higher risk of CKD progression. However, the clinical significance of blood pressure was less powerful than remission status.

Keywords: Blood pressure; Chronic kidney disease; Focal segmental glomerulosclerosis; Glomerular disease; IgA nephropathy; Membranous nephropathy.

PubMed Disclaimer

Comment in

References

    1. Becker GJ, Wheeler DC, De Zeeuw D, Fujita T, Furth SL, Holdaas H et al (2012) Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2(5):337–414 - DOI
    1. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI et al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2255–2266 - DOI
    1. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16(4):1061–1068 - DOI
    1. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S et al (1995) A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48(5):1600–1604 - DOI
    1. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C et al (1989) A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320(1):8–13 - DOI

LinkOut - more resources